Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

Transposagen Biopharmaceuticals Inc. signed an exclusive licensing deal with Charles River Laboratories International Inc. (NYSE:CRL) for lab rats. Under the agreement, Wilmington, Mass.- ...

In a report released yesterday, Charles Rhyee from TD Cowen maintained a Hold rating on Charles River Labs (CRL – Research Report), with ...

Charles River Laboratories International Inc (NYSE:CRL) reported third-quarter 2024 revenue of $1.01 billion on Wednesday, a ...

Charles River Laboratories Intl ( (CRL)) has released its Q3 earnings. Here is a breakdown of the information Charles River Laboratories Intl presented to its investors. Charles River Laboratories ...

Charles River Laboratories International Inc. could share more details this week about the “restructuring initiatives” it is ...

James Foster; Chairman of the Board, President, Chief Executive Officer; Charles River Laboratories International Inc Flavia Pease; Chief Financial Officer, Corporate Executive Vice President ...

Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and ...

Charles River Laboratories International Inc (NYSE:CRL) exhibits resilience despite a challenging market environment. Strategic acquisitions and a diversified service portfolio position CRL for ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a ...